PD-L1 x Immune Stimulatory Agent

Our therapeutic goal is to develop an anti-PD-L1 antibody that will both effectively block PD-1:PD-L1 interaction and help increase cytotoxic T lymphocyte (CTL) activity through the directed delivery of an immune stimulatory agent (ISA) to the site of the tumor while reducing the adverse side effects of untargeted systemic delivery of the same ISA.

IGM’s PD-L1 x ISA antibody has 10 binding units which may allow binding to those tumor cells which display relatively small amounts of PD-L1. In addition, our 10 to 1 ratio of PD-L1 to ISA and our targeted delivery of the ISA may prove to be safer than untargeted systemic delivery of the ISA.